Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan, capecitabine (Xeloda) and bevacizumab (Avastin) in previously untreated metastatic colorectal cancer
2008-004688-20Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and irinotecan in metastatic colon cancer (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: progression-free survival at 9 months. Started Nov 2008; status: completed.
02
Drugs
bevacizumabcapecitabineirinotecan
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2008-004688-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004688-20.